A General Strategy for Targeting Drugs to Bone
Dr. Wolfgang Jahnke, Dr. Guido Bold, Dr. Andreas L. Marzinzik, Dr. Silvio Ofner, Xavier Pellé, Dr. Simona Cotesta, Emmanuelle Bourgier, Sylvie Lehmann, Chrystelle Henry, René Hemmig, Dr. Frédéric Stauffer, Dr. J. Constanze D. Hartwieg, Dr. Jonathan R. Green and Dr. Jean-Michel Rondeau
Article first published online: 12 OCT 2015 | DOI: 10.1002/anie.201507064
To the bone: Drugs for bone diseases benefit from targeting to bone. Bone-affinity tags are presented that can be attached to bone-acting drug molecules to make them safer and more efficacious, while retaining desired properties such as cellular permeability and oral bioavailability. This was demonstrated for allosteric inhibitors of farnesyl pyrophosphate synthase.